Lateral Flow Assays Industry Overview

The global lateral flow assays market size is expected to reach USD 13.60 billion by 2030, registering a CAGR of 4.26% over the forecast period, according to a new report by Grand View Research, Inc. Major factors driving the growth include the rising prevalence of infectious diseases, growing government initiatives to curb infectious and chronic diseases, rise in demand for point-of-care testing, and increasing strategic mergers acquisitions among others.

Lateral flow assays were developed about half a century ago and have facilitated several diagnostic and testing applications in domains such as healthcare, food beverage testing, and environmental testing. Similarly, lateral flow assay applications in point-of-care diagnostics are growing and are propelling significant advancements in research for the development of products that evaluate body fluids, such as urine and saliva.

The use of these devices promotes self-testing, reduces the need for laboratory testing, and eliminates the need for trained laboratory personnel. Although there have been several technological advancements in laboratory testing in the recent past, several emerging economies still face challenges regarding timely medical intervention. This represents a major factor that is driving the adoption of dipsticks or lateral flow assays for facilitating timely diagnosis and treatment.

Gather more insights about the market drivers, restrains and growth of the Lateral Flow Assays Market

Due to the increasing utility of lateral flow assays for home use and self-testing, several at-home tests were launched after the pandemic began. For instance, tests such as Abbott’s BinaxNOW COVID-19 Antigen Self-Test, Access Bio’s CareStart COVID-19 Antigen Home Test, Becton, Dickinson and Company’s BD Veritor At-Home COVID-19 Test, and Ellume’s COVID-19 Home Test are commercially available.

Government initiatives supporting the use of such tests are expected to enhance the penetration of lateral flow assays and can aid in driving the lateral flow assays market growth. For instance, the Biden-Harris administration has incentivized health plans and insurers for installing a network of locations across the country for providing at-home, over-the-counter COVID-19 tests for free to people with private health coverage.

Continuous strategic initiatives undertaken by leading and emerging players to develop and launch advanced products are anticipated to significantly support market growth. For instance, in November 2021, IUL SA launched the iPeak Europium, a new lateral flow reader used to scan fluorescence-labeled lateral flow tests. Similarly, in March 2021, the company introduced its new lateral flow reader, iPeak+.

Additionally, in January 2021, Sensyne Health, based in the U.K., introduced an innovative smartphone app-MagnifEye-that employs deep machine learning AI to automate the interpretation of lateral flow diagnostic tests. A rise in mergers and collaborations by market players is anticipated to facilitate access to novel lateral flow technologies.

For instance, in February 2022, U.S.-based BD (Becton, Dickinson and Company) and Scanwell Health collaborated to create an at-home rapid test for SARS-CoV-2 using a BD lateral flow antigen test and the Scanwell Health mobile app. The collaboration aims to provide an efficient and scalable rapid antigen home testing solution.

The use of lateral flow devices also eliminates the need to wait for deciphering test results as well as aids in the optimization of timely treatment decisions, improves the efficacy of care provided, and significantly reduces diagnosis costs, especially in areas with resource-constrained settings and insufficient laboratory infrastructure. The rising trend of decentralized testing has been crucial in increasing the adoption of lateral flow devices globally.

The role of these devices has also been observed in controlling major infectious diseases such as malaria and influenza. According to WHO, rapid diagnostic tests are used in diagnosis by healthcare professionals distant from microscopy services; remote diagnosis by professionals in malaria54-endemic countries; and outbreak investigation survey of parasite prevalence. Thus, various benefits offered by lateral flow devices are among the key factors responsible for increasing the adoption of lateral flow assays globally.

On the other hand, with the advent of advanced technologies, such as PCR and molecular diagnostics, the demand for lateral flow assays may be witnessing sluggish growth to a certain extent. Although lateral flow assays have high specificity and sensitivity, PCR and other molecular diagnostic technologies have emerged to be more sensitive.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global next-generation sequencing data analysis market size was valued at USD 999.4 million in 2024 and is expected to expand at a CAGR of 23.10% from 2025 to 2030. 
• The global stem cell therapy market size was estimated at USD 456.0 million in 2024 and is expected to grow at a CAGR of 25.23% from 2025 to 2030.

Lateral Flow Assays Market Segmentation

Grand View Research has segmented the global lateral flow assays market on the basis of product, application, technique, test-type, end-use, and region:

Lateral Flow Assays Product Outlook (Revenue, USD Million, 2018 - 2030)

• Kits Reagents
• Lateral Flow Readers
  • Lateral Flow Readers
  • Benchtop Readers
  • Digital Readers

Lateral Flow Assays Application Outlook (Revenue, USD Million, 2018 - 2030)

• Clinical Testing
  • Infectious Disease Testing
    • COVID-19
    • Mosquito Borne Disease Testing
    • Influenza Testing
    • Sexually Transmitted Infection Testing
      • STI Testing
      • HIV Testing
      • HPV Testing
      • Chlamydia Testing
      • Gonorrhea Testing
      • Syphilis Testing
      • Other STI Testing
    • Hepatitis
    • Tuberculosis
    • Other Infectious Diseases
  • Cardiac Marker Testing
    • Troponin I and T Testing
    • CK-MB Testing
    • BNP and NT-Probnp Testing
    • Myoglobin Testing
    • D-Dimer Testing
    • Other Cardiac Marker Tests
  • Pregnancy Fertility Testing
    • Pregnancy Testing
    • Fertility Testing
  • Cholesterol Testing/Lipid Profile
  • Drugs of Abuse Testing
  • Other Clinical Tests
• Veterinary Diagnostics
• Food Safety Environment Testing
• Drug Development Quality Testing

Lateral Flow Assays Technique Outlook (Revenue, USD Million, 2018 - 2030)

• Sandwich Assays
• Competitive Assays
• Multiplex Detection Assays

Lateral Flow Assays Test-type Outlook (Revenue, USD Million, 2018 - 2030)

• Lateral Flow Immunoassay
• Nucleic Acid Lateral Flow Assay

Lateral Flow Assays End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals Clinics
• Diagnostic Laboratories
• Home Care
• Pharmaceutical Biotechnology Companies
• Others

Lateral Flow Assays Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

Key Companies profiled:

• Abbott Laboratories
• Thermo Fisher Scientific, Inc.
• Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc
• bioMérieux SA
• Quidel Corporation
• Hologic, Inc.
• PerkinElmer, Inc.
• Merck KGaA
• BD
• Siemens Healthineers
• Danaher Corporation
• QIAGEN N.V.

Order a free sample PDF of the Lateral Flow Assays Market Intelligence Study, published by Grand View Research.